Galapagos Flies As Filgotinib Soars In FINCH Studies
More evidence of its strong safety profile suggests that the Belgian biotech's oral selective JAK1 inhibitor partnered with Gilead will be able to break into the crowded RA market.
You may also be interested in...
Galapagos is another step closer to commercializing its products with its lead candidate, filgotinib, now under the gaze of EU regulators.
Having signed a major alliance expansion with Gilead, Onno van Stolpe tells Scrip that any takeover talk about Galapagos would be "unacceptable and unwanted."
Concerns the Galapagos-partnered JAK inhibitor would be held back by a testicular toxicity study have been calmed by positive FDA talks and a submission is due before the end of the year.